Relmada Therapeutics Inc (RLMD)
3.35
-0.14
(-4.01%)
USD |
NASDAQ |
May 17, 16:00
3.35
0.00 (0.00%)
After-Hours: 20:00
Relmada Therapeutics Cash from Operations (Quarterly): -13.04M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -13.04M |
| December 31, 2023 | -10.25M |
| September 30, 2023 | -11.63M |
| June 30, 2023 | -13.27M |
| March 31, 2023 | -16.51M |
| December 31, 2022 | -35.88M |
| September 30, 2022 | -26.86M |
| June 30, 2022 | -21.63M |
| March 31, 2022 | -19.43M |
| December 31, 2021 | -37.66M |
| September 30, 2021 | -20.92M |
| June 30, 2021 | -17.21M |
| March 31, 2021 | -16.09M |
| December 31, 2020 | -6.929M |
| September 30, 2020 | -12.50M |
| June 30, 2020 | -4.954M |
| March 31, 2020 | -3.425M |
| September 30, 2019 | -2.534M |
| June 30, 2019 | -3.667M |
| March 31, 2019 | -2.012M |
| December 31, 2018 | -3.148M |
| September 30, 2018 | -1.671M |
| Date | Value |
|---|---|
| June 30, 2018 | -2.266M |
| March 31, 2018 | -1.625M |
| December 31, 2017 | -1.132M |
| September 30, 2017 | -0.979M |
| June 30, 2017 | -1.016M |
| March 31, 2017 | -1.855M |
| December 31, 2016 | -1.450M |
| September 30, 2016 | -2.144M |
| June 30, 2016 | -2.826M |
| March 31, 2016 | -3.627M |
| December 31, 2015 | -3.475M |
| September 30, 2015 | -3.216M |
| June 30, 2015 | -4.489M |
| March 31, 2015 | -4.432M |
| December 31, 2014 | -4.984M |
| September 30, 2014 | -2.322M |
| February 28, 2014 | -0.0035M |
| November 30, 2013 | -0.0091M |
| August 31, 2013 | -0.0054M |
| May 31, 2013 | -0.005M |
| February 28, 2013 | -0.0029M |
| November 30, 2012 | 0.0015M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-37.66M
Minimum
Dec 2021
-2.534M
Maximum
Sep 2019
-15.49M
Average
-13.27M
Median
Jun 2023
Cash from Operations (Quarterly) Benchmarks
| Cyclacel Pharmaceuticals Inc | -3.91M |
| Lifecore Biomedical Inc | -17.29M |
| Harrow Inc | -4.628M |
| Corvus Pharmaceuticals Inc | -5.157M |
| Aquestive Therapeutics Inc | -10.38M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 10.06M |
| Cash from Financing (Quarterly) | 0.2217M |
| Free Cash Flow | -48.19M |
| Free Cash Flow Per Share (Quarterly) | -0.4327 |
| Free Cash Flow Yield | -47.92% |